News

The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for

Robert Melamede, president and CEO of Cannabis Science, said: “We are in the final stages before Cannabis Science files with the FDA for clinical trials. There is a

The article, entitled ‘Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices,’ was published in the February 2010 issue of the journal Community Oncology.

A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin. Data from the study will be submitted for presentation at the American Society

The 15-year clinical study demonstrated that more than 80% of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of

NextBio Enterprise offers life sciences organisations tools for knowledge discovery and collaboration, seamless integration of internal and external research data, and secure data access. Saeid Akhtari, co-founder and

The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex’s development plan regarding the proposed preclinical

Genta has recently completed a dose-ranging and pharmacokinetic study using Tesetaxel administered once every 3 weeks, a schedule that has shown anticancer activity in several Phase 2 clinical

Reportedly, Kyowa Hakko Kirin has confirmed KW-2246’s safety and efficacy in clinical trials conducted in Japan. The drug will be marketed by Kyowa Hakko Kirin and Hisamitsu Pharmaceutical.